The NRG/Alliance LU005 trial evaluated the efficacy of adding atezolizumab to concurrent chemoradiation therapy (CRT) in patients with limited-stage small cell lung cancer (LS-SCLC). Enrolled patients were randomly assigned in a 1:1 ratio to receive either CRT alone or CRT plus concurrent and adjuvant atezolizumab (1,200 mg daily every 3 weeks).1
The final results showed no improvement in overall survival (OS) or progression-free survival (PFS) with concurrent and consolidative atezolizumab compared with CRT alone. These findings align with data from other trials across various tumor types that have also demonstrated no benefit of concurrent immunotherapy and radiotherapy (RT).
In an editorial commentary about the trial, Adam J. Schoenfeld, MD, and Florence K. Keane, MD, note that the results from NRG/Alliance LU005 contribute to a growing body of evidence suggesting a lack of benefit from concurrent immunotherapy and RT.2
Dr. Schoenfeld, a Medical Oncologist at Memorial Sloan Kettering Cancer Center and Assistant Professor of Medicine at Weill Cornell Medical College, expanded on the analysis of the findings from NRG/Alliance LU005 in a recent interview with ILCN.
ILCN: What might explain the lack of survival benefit when these treatments are administered together in LS-SCLC?
Dr. Schoenfeld: The most likely explanation is that the issue is not whether immunotherapy and RT can work together, but rather when they are introduced relative to one another. LU005 adds to a now fairly consistent pattern across thoracic oncology: When checkpoint blockade initiation overlaps with chemoradiotherapy, we have not seen the magnitude of benefit many hoped for, whereas the benefit can be substantial when immunotherapy is given after the completion of CRT—as in the ADRIATIC trial.
One plausible biologic explanation is that thoracic RT may impair the very immune response that checkpoint blockade is meant to trigger and amplify. In LS-SCLC, radiation fields often include mediastinal structures and nodal basins, exposing draining lymph nodes and circulating lymphocytes to radiation.
This can promote lymphopenia and potentially blunt the effective priming and expansion of antitumor T cells. At the same time, initiating PD-(L)1 blockade during CRT may not provide the same immune context as starting it after patients have completed local therapy and recovered from its immunologic effects.
To me, LU005 supports the idea that the lack of benefit is less about the combination itself and more about the biologic consequences of overlapping these modalities during a vulnerable immunologic window.
ILCN: The ADRIATIC trial demonstrated a nearly 3-year improvement in median OS with consolidative durvalumab after CRT in LS-SCLC. What lessons can be drawn from the differences in outcomes between these two trials?
Dr. Schoenfeld: I think timing is the central lesson. The ADRIATIC and LU005 trials are especially informative when viewed together because they tested similar components in the same disease setting but with very different sequencing.
ADRIATIC demonstrated a major survival improvement with immunotherapy after CRT, whereas LU005 did not show any benefit with concurrent and consolidative atezolizumab. This contrast strongly suggests that timing matters.
More broadly, this fits a larger theme in oncology: The first doses of immunotherapy may be especially important, and their impact may depend on the state of the tumor microenvironment and the host immune system at that moment. If checkpoint blockade is introduced when lymphocytes are being depleted or functionally disrupted by thoracic radiation, the immune system may be less capable of mounting the durable antitumor response we want.
By contrast, giving immunotherapy after CRT may allow clinicians to capitalize on tumor antigen release from radiation while avoiding direct overlap with some of the most immunosuppressive effects of treatment. For this reason, I do think the field should shift from simply asking whether these treatments should be combined to asking when immunotherapy should begin in order to maximize efficacy.
ILCN: What considerations should oncologists consider regarding the side effects of combining immunotherapy with RT? Do the toxicity risks outweigh the potential benefits?
Dr. Schoenfeld: The main concern is overlapping toxicity in organs already stressed by thoracic CRT, especially the lungs and esophagus. When immunotherapy is layered onto concurrent CRT, clinicians naturally worry whether inflammatory toxicities may be amplified, and whether immune-related adverse events could complicate recovery from chemoradiation.
In LU005, the rates of grade 3 or higher pneumonitis and esophagitis were not dramatically different between treatment arms, which is reassuring to some degree. At the same time, the overall experience with concurrent immunotherapy across thoracic trials has not shown a clear efficacy payoff, and some studies have suggested more toxicity, or, at a minimum, more treatment complexity. So, even if the added toxicity is not prohibitive in every study, the key question is whether any added risk is justified by clinical benefit. In LU005, the answer appears to be no.
I would therefore frame this less as concurrent immunotherapy being categorically too toxic and more as the risk-benefit balance being unfavorable in the absence of efficacy. Without a clear survival or disease-control advantage, even modest added toxicity, monitoring burden, and treatment complexity become hard to justify.
ILCN: What other factors might have contributed to the NRG/Alliance LU005 results?
Dr. Schoenfeld: Several additional factors are worth considering. One is that the population enrolled in concurrent trials differs fundamentally from the population enrolled in consolidative trials.
In a concurrent design, patients are randomized earlier, at diagnosis, which includes some patients who may never derive benefit from later therapy because they progress early or do not tolerate treatment well. By contrast, consolidative trials select patients who have completed CRT without progression and remain fit enough to proceed. That said, the strong outcomes observed in the control arm of LU005 suggest that this alone probably does not explain the negative result.
It is also possible that radiation-related immune effects still played an important role beyond timing alone. Even with high-quality RT planning, thoracic radiation can expose mediastinal structures, draining lymph nodes, and circulating lymphocytes in ways that suppress systemic immunity and potentially blunt the benefits of checkpoint blockade.
Another point is that LU005 reminds us how much the treatment backbone still matters. The exploratory analyses suggesting better outcomes with twice-daily RT and possible differences related to cisplatin versus carboplatin raise the possibility that optimizing CRT may have as much influence on outcomes as adding a checkpoint inhibitor.
At the same time, this was a well-conducted cooperative group trial with rigorous radiation quality assurance and high protocol compliance. In some ways, that makes the negative result more convincing, because it is less likely to be explained by poor treatment delivery.
ILCN: What are the most important takeaways from the LU005 trial that clinicians should consider incorporating into their practice?
Dr. Schoenfeld: The clearest takeaway is that concurrent and consolidative atezolizumab should not replace the current standard approach in LS-SCLC. LU005 did not show an improvement in OS or PFS, so these data do not support the routine use of concurrent checkpoint blockade with CRT in this setting.
Equally important, the trial strengthens the case that sequencing matters. In practical terms, it supports the current momentum behind consolidation after CRT, as established by ADRIATIC, rather than overlapping immunotherapy concurrently with radiation upfront.
At the same time, it leaves open an important question for the field: Whether immunotherapy given before CRT, rather than during or after it, could prove more effective and deserves ongoing prospective study.
The study also reinforces the importance of getting the CRT backbone right. The exploratory signal favoring twice-daily RT adds further support to a regimen that already has strong evidence behind it and should remain a serious consideration for eligible patients.
More broadly, LU005 is a reminder that negative phase III trials can still be highly practice-informing. This study helps clarify what not to do, sharpens our biological hypotheses, and should push the field toward smarter sequencing strategies and more biomarker-rich prospective studies, rather than simply adding checkpoint inhibitors concurrently by default.
References
- 1. Higgins KA, Hu C, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, Ritter TA, Williams TM, Welsh J, Simko JP, Movsas B, Xiao C, Kaira K, Gupta AK, Mohindra P, Dib EG, Brownstein J, Chun S, Kuzma CS, Kotecha R, Onitilo AA, Chen Y, Stinchcombe TE, Wang X, Paulus R, Bradley JD. Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. J Clin Oncol. 2026 Mar 10;44(8):630-640. doi: 10.1200/JCO-25-01569. Epub 2026 Jan 13. PMID: 41529214; PMCID: PMC12874332.
- 2. Keane FK, Schoenfeld AJ. Timing Is of the Essence: Sequencing Immune Checkpoint Blockade and Radiotherapy for Success in Lung Cancer. J Clin Oncol. 2026 Mar 10;44(8):613-621. doi: 10.1200/JCO-25-02726. Epub 2026 Jan 14. PMID: 41534001.
